secretinvestor8888

sell topglove = sell supermax = sell hartalega = sell kossan ...
Don't be like a joker....

History and Trend is there. Should be uptrend further tomorrow

wow now Supermx and Kossan same price 10.48 ….
Macam English Premiere League race ...

already up so much , profit taking Is normal ….
don't ask why hahaha

profit taking ...those contra players , pandai pandai …

"If the vaccine is successful, the companies expect to manufacture up to 100 million doses by the end of this year and potentially more than 1.2 billion doses by the end of 2021. They would jointly to distribute the product worldwide except in China, where BioNTech has a collaboration with Fosun Pharma"

Again , if successful......So is Still unknown...

With new TP 18.16 from KNG ib . Tomorrow many will add and sapu this counter for sure .
Will be another Top Glove .

Hartalega Holdings- Quantum Leap in Earnings


Date: 01/07/2020


Source : KENANGA
Stock : HARTA Price Target : 18.16 | Price Call : BUY
Last Price : 14.78 | Upside/Downside : +3.38 (22.87%)




Taking the cue from the other glove players’ quarterly earnings announcements over the past month, we are raising our assumptions for HARTA. Specifically, the industry trend of rising ASPs is expected to substantially boost its bottom-line. Our analysis further suggests that ASP is expected to stay elevated over the next few quarters. Hence, we raised our FY21E/FY22E net profit by 47%/53%. TP is raised from RM13.90 to RM18.16 based on 43x CY21E EPS. Reiterate OP.

Expect quantum leap in earnings. Strong QoQ earnings results of glove players over the past month suggest that demand will be strong over the next few quarters with industry ASP higher on a weekly and monthly basis. Anecdotal evidence suggests that rubber glove players’ explosive QoQ earnings growth is expected to sustain over the next few quarters. Judging by the results of other players over the past two weeks only, we are raising our assumptions for HARTA. Specifically, the industry trend of rising weekly and monthly ASPs between 5% to +15% is expected to boost its bottom-line.

Our analysis suggests shortage in supply. We have done an analysis to dispel any concerns of gloves oversupply. In anticipation of higher demand due to the pandemic, stock piling and entrant of new users, players are raising capacities to meet the surging demand. Our analysis (see table overleaf) suggests that acute supply and supernormal demand could persist over the next two years. Interestingly, players are getting orders from new users including airlines, restaurants, retail apparel chains and hotel operators. If we look at the capacity expansion numbers in isolation, it looks overwhelming. But viewed against the incremental new pandemic driven demand in addition to the annual base level demand growth, the additional capacity is not a concern. In fact, the estimated new yearly capacity may not actually start as scheduled and hence the supply shortage will continue to be acute in 2021. Typically, to cater for normal demand, glove makers essentially need to build just one plant per year. However, from channel checks, to cater for this current pandemic driven demand, two to three plants are required for each glove maker (on average) annually in order to meet the supernormal demand, which takes between 12 to 24 months to complete. Hence, we conclude that ASP tightness will continue going into 2021. We highlight that a player in China ramping up capacity by 30b pieces over 2-3 years could take longer than expected as it typically takes 8 to 10 years to build such a capacity.

China and low user per capita countries are potential high growth markets. We expect gloves consumption per capita in China to surge sharply following the COVID-19 experience. For illustration purposes, assuming a population of 1.4b and conservative 30 gloves per capita (from currently 9 – please refer to chart overleaf - compared to developed western countries which averaged 200 pieces per capita), this implies a massive 42b piece (from currently 2.8bn pieces) of rubber gloves consumption in China annually. Hence, any new supply from the Chinese players could be absorbed domestically.

Raised FY21E/FY22E net profit by 47%/53% after: (i) imputing higher ASP from USD29/1,000 pieces to USD30.50/1,000 pieces for each year, and (ii) assuming higher EBITDA margin of 35% compared to 26.5% previously. We raised our FY22E utilisation to 100% from 97%.

Reiterate OP. TP is raised from RM13.90 to RM18.16 based on 43x CY21E revised EPS (previously 50x) (at slightly below +2.0SD above 5- year historical forward mean). We lowered our PER rating as we believe valuations are pegged to supernormal earnings; hence, upside to peak earnings should have been factored in. We like Hartalega for: (i) its solid management, (ii) constantly evolving via innovative products development, and (iii) its booming nitrile gloves segment.

Risks to our call: lower-than-expected ASPs and volume sales

Source: Kenanga Research - 1 Jul 2020

Wait it drop till below 0.60...then can sapu

permaju drop till like no tomorrow

this counter almost everyday promoting itself on newspaper ….
but price keep going down...

Tomorrow will green .
Down Jones futures turn from deep red to green now

market drop because of COVID-19 2nd wave fear ...Glove counter will be getting more benefits from it

realdeal46, no need to ask for limit up, if today can close above 17.00 will be good enough

managed to captured @ 16.00

Don't be fooled by vaccine news .
Even the vaccine is available , glove demand is still high. Do you think that people don't use glove after vaccine available ?

Near 350mil

Very good results !!

I just finished watching movie ..then come here look see look see.. I see still have many people here still not yet sleep ..
May be tonight can't sleep haha

This company still consider healthy and have good fundamental

In this forum ,although I have no more holding health care counter share, but I don't call for the share price to drop or hope for the share price to limit down. Is very very bad attitude to do so..

cwscws to be frank, I dont dare to get the vaccine ...have no confident at all. Because apparently all the vaccine manufacturer are racing each other may just claim theirs is the best , but actually is not 100% working ...

what an amazing news from careplus ..wish to add more on Tuesday , but I think no chance to grab at lower price than 1.70..

Very positive new for careplus today.
Tuesday will be seeing a good show from this counter

Glove counters like Top Glove and Supermax has hugh order with full capacity of production until 2021. The price is justified with TP from IB.

AstraZeneca is aiming to produce 2 billion doses of a coronavirus vaccine — and it could be ready by September
PUBLISHED THU, JUN 4 20202:57 PM EDTUPDATED AN HOUR AGO
Lucy Handley
@LUCYHANDLEY
----------

It is a competition and every single pharmaceutical company would like to make news to show their capability to their shareholders. But the reality is no company want to be the first to provide the vaccine.

It comes with great responsibility and huge credibility risk! If the vaccine works on the first 10,000 human but fails on others, the company brand and reputation will go down the drain. A single mistake that could cause the entire company go bankrupt!

September is just too soon.

Would you dare and confident to try a vaccine that is produced in just short period of time?
No body dare...

AstraZeneca chief executive Pascal Soriot said he expects to know by August if the AZD1222 vaccine is effective, while CEPI chief executive Richard Hatchett said there is still a possibility the vaccine may not work.

Business man says vaccine may be ready soon ...but expert says vaccine may not work well..
Business man shiok sendiri ….

look at top glove , marching today day high ...wow

tomorrow will be hitting and pass RM 16.00

Just around 9 working days more to go...
Start to accumulate before it reach TP

yah , TOP mask is coming soon , from Top Glove …
Cant imagine how high would be the TP for Top Glove .
Accumulate now since most of the IB has revised the TP to 20.00

Good news . Tomorrow will accumulate K1 and wait for the handsome return!!

Top Glove correction ended . Will start to up steadily from tomorrow onwards..

KUALA LUMPUR (June 3): AmInvestment Bank Research has maintained its “Overweight” rating on the glove sector and said that selling prices will continue to soar for the next 12 months as lead time stretches up to 12 months.

In a sector note today, the research house said the glove companies’ earnings will be further pushed by expanded margins as raw material prices remain low, selling prices continue to grow, US dollar continues to strengthen over ringgit and expansion plans remain intact for the glove producers.

“Our house projection for the USD/MYR rate is an average of RM4.29 in 2020 and RM4.25 in 2021.

“We think that a stronger ringgit will even help further expand net margins for glove companies because unlike pre-Covid-19 times, cost savings are not passed through to customers due to supply constraints,” it said.

AmInvestment said glovemakers are now expecting glove demand to increase by roughly 30–50% (8–10% pre-Covid-19).

It said the higher demand has resulted in a shortage of supply, pushing up average selling prices for these medical gloves.

“Average selling prices (ASP) are trending upwards and glovemakers now guide for around 5–15% quarter-on-quarter gradual increases while spot selling prices for gloves skyrocketed 100–400% in the past few months as panic buying of gloves ensues.

“We raise our ASP assumptions for the glovemakers by around 2–9% . We believe selling prices will continue to grow in 2021 as a vaccine for Covid-19 is expected to take roughly 12–18 months to create,” it said.

Sarara the fundamental for glove counter is there. Some counters like Top Glove and Supermax, the new TP by IB not even reach yet.So what risk are you talking about? Unless you are contra player .

good to collect at cheaper price !! Top Glove TP = RM 20.00

I would say today is a healthy correction ...Those counters are taking a good rest for a day . Tomorrow get ready to climb again. So there is no need to be worried or panic. Go enjoy your Latte or Teh Tarik.

Don't think the price will drop. Today Adventa was limit up since morning session.Many people would have known that the price will be freezed and sell off today afternoon.

today many health care counters SOLD OUT....Really sell like a hot cake today!!

Talking about vaccine, now the vaccine still in very very initial stages , not even having halfway of the journey ….
To produce a proven vaccine needs a lots of clinical PROVEN data , including 0% side effect . Then only can call a true vaccine …
So is still long way to go ….

TP by Kenanga IB 7.60 is just around the corner. Should not be any problem to TOUCH n GO

super good show by Supermax ….totally outstanding !!
Tonight shall celebrate all night long ...

Early morning good show !!

Health care counter already immune to whatso ever vaccine news!

Whether the Vaccine on covid19 will be successful is still a big question mark. It will be long way to go.
Now many biotech company just trying to show how capable they are especially USA and China.

Is good that currently many countries had started to develop vaccine for Covid-19 in order to resolve this deadly sickness..
But to develop a vaccine that is effective to stop Covid-19 is not one or two days and it would take years to be proven. Moreover, this new vaccine is still on trial , and has not proven anything yet .Even medical experts do not put on high hope on this vaccines..

Lets see how tomorrow the gloves counters in actions in Bursa. Today most of the glove counters in SGX doing well...

Alex Carchidi(TMFacarchidi)
May 24, 2020 at 9:16AM
Novavax (NASDAQ:NVAX) is developing a COVID-19 vaccine candidate, and recent spikes in its stock price and trading volume indicate that investors suspect such a treatment could give the company another chance at life.

Novavax is far from a healthy business, however. The company's vaccine trials in 2016 and 2019 ended in embarrassing and costly late-stage failures due to a lack of clinical efficacy, and it's never successfully brought a product to market.

Goosem, are you telling all of us this embarrassing "succesful" story from Novavax previously?

You won't get trapped for holding this share until next Q results....IB stated the TP price is for coming Q results...
Be a smart invester…..

CIMB and Kenanga IB had mentioned TP = 6.5 and 7.5 respectively ...Lets see if this TP could achived by this month...